Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases
A legfontosabb adatok
- Ki végzi
- UMC Utrecht
- Hol
- Amsterdam, Heerlen, Nijmegen, Rotterdam, The Hague és Utrecht (Hollandia)Mind a 6 helyszín megnézése
- Azonosító
- Állapot
- Toboroz
- Fázis
- 2. fázis
- Résztvevők
- 60 fő, tervezett
- Kezdés
- 2024. márc. 12.
- Várható befejezés
- 2027. dec.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- Filgotinib
- A regiszteradat frissítve
- 2026. május 12.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with active, hard-to-treat Behçet's disease, dermatomyositis or anti-synthetase syndrome (myositis), or IgG4-related disease. They will take Filgotinib for 26 weeks.
- Életkor
- 18 years or older; people aged 65 or older cannot join.
- Nem
- All sexes.
- A betegség stádiuma
- Active disease, shown by a disease score (BDCAF >2 new or >15 old; CDASI ≥5; IgG4-RD responder index >10), muscle enzymes ≥4× upper limit of normal, an MRI showing inflammation in the last 3 months, or the need for new medication. Behçet's disease must not have refractory life, organ or sight-threatening symptoms.
- Korábbi kezelés
- Disease stays despite a 12-week trial of glucocorticoids, plus no response to at least one other immune-lowering drug (such as MTX, MMF, AZA or rituximab), or intolerance to standard care. People who used other JAK inhibitors before cannot join.
- Biomarker vagy leletérték
- Negative QuantiFERON-TB Gold In-Tube test and negative Mantoux skin test for tuberculosis, done at or within 3 months before screening.
A részvétel fő kizáró okai
- Juvenile DM, myositis overlapping with other autoimmune diseases, IMNM, inclusion-body myositis or cancer-related myositis
- Active infection, HIV, hepatitis B or C, active or poorly treated tuberculosis, shingles or repeated herpes
- Cancer in the last five years or higher cancer risk, except treated basal or squamous skin cancer
- Higher risk of major heart and blood vessel problems, or current or long-term past smoking
- Pregnancy or breastfeeding
A regiszter feltételei, szó szerint
Mind a 28 feltétel megnézéseKevesebb
Ki vehet részt
- Age 18 years of older
- One of the following rare IMIDs:; Diagnosis of Behçet's disease without refractory life, organ or sight-threatening symptoms with active disease, defined as a BDCAF >2 (new BDCAF) or >15 (old BDCAF) or with active disease, based on clinical grounds (e.g. the need to start new or additional medication; Diagnosis of idiopathic inflammatory myopathy, according to diagnostic criteria:; Dermatomyositis: Dermatomyositis Classification Criteria according to the European Neuromuscular Centre guidelines 201852 or anti-synthetase syndrome: Anti- synthetase syndrome Classification Criteria according to the European Neuromuscular Centre guidelines 200353, both with active disease, defined as a CDASI score of ≥5 or abnormal levels of at least 1 of the following enzymes: creatine kinase (≥ 4× upper limit of normal [ULN]), aldolase (≥4 × ULN), lactate dehydrogenase (LDH ≥4 × ULN), aspartate transaminase (AST ≥4 × ULN), alanine aminotransferase (ALT ≥4 × ULN) or a MRI within the last 3 months indicative of active inflammation (e.g. edema signal pattern in affected proximal muscles) or active disease based on clinical grounds, e.g. the need to start new or additional medication
- Diagnosis of IgG4-related disease, according to 2019 ACR/EULAR guidelines, with active disease, defined as: IgG4-related disease responder index >10 or active disease based on clinical grounds, e.g. the need to start new or additional medication; Refractory disease, defined as symptomatic disease that persists despite a 12-week trial of glucocorticoid therapy as well as lack of response to at least one other immunosuppressive agent such as methotrexate (MTX), mycophenolate mofetil (MMF), azathioprine (AZA) or rituximab or intolerance to standard-of-care treatment, as defined by the treating physician; No evidence of active or latent or inadequately treated infection with mycobacterium tuberculosis (TB) as defined by all of the following: both a negative QuantiFERON-TB Gold (QFT-G) In-Tube test and a Mantoux tuberculin skin test performed at or within 3 months prior to screening and no signs suggestive of active TB infection as determined (and documented) by a qualified radiologist or pulmonologist as per local standard of care on a chest radiograph and no history of either untreated or inadequately treated latent or active TB infection
Ki nem vehet részt
- Previous use of other JAK inhibitors
- Use of any investigational drug within one month prior to screening or within five half-lives of the investigational agent, whichever is longer
- Known recent substance abuse (drugs or alcohol)
- Previous non-adherence to immunosuppressants
- Juvenile DM, myositis overlapping with other autoimmune diseases, immune mediated necrotizing myopathy (IMNM), inclusion-body myositis or cancer-associated myositis
- End-stage IIM wherein muscle weakness is most likely due to muscle damage, rather than myositis disease activity
- Human Immunodeficiency Virus (HIV) infection
- Presence of an active infection or viral hepatitis type B or C
- History of shingles or recurrent herpes simplex infection
- Concomitant malignancies or previous malignancies within the last five years (with exception of adequately treated basal or squamous cell carcinoma of the skin)
- Increased risk of cancer
- Liver failure Child Pugh C
- Hypersensitivity to the active substance or to any of the excipients
- Absolute neutrophil count <1*109
- Absolute leukocyte count <0.5*109
- Hemoglobin <5mmol/L - Inability to comply with study and/or follow-up procedures
- Rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption
- Age <18 years
- Age ≥65 years
- Life expectancy less than 6 months
- Increased risk of major cardiovascular problems
- Current smoker or smoked for a long time in the past
- Pregnancy or lactation
- Kidney injury with estimated glomerular filtration rate <15mL/min/1.73m2
- Poor tolerability of venipuncture or lack of adequate venous access for required blood sampling during the study period
A fő feltételek kérdésként
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 65 év között vagy?
Ez a vizsgálat jelenleg itt érhető el: Hollandia.
- Amsterdam UMCAmsterdam, HollandiaContact: Joost Raaphorst, Dr.Résztvevőt keres
- Zuyderland Medical CenterHeerlen, HollandiaContact: Cesar Magro Checa, DrRésztvevőt keres
- Radboud University Medical CenterNijmegen, HollandiaContact: Rogier Thurlings, DrRésztvevőt keres
- Erasmus MCRotterdam, HollandiaContact: Jan van Laar, Dr.Résztvevőt keres
- HagaZiekenhuisThe Hague, HollandiaContact: Robbert J Goekoop, MDRésztvevőt keres
- University Medical CenterUtrecht, HollandiaContact: Anne Karien Marijnissen, Dr.Résztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
Research into novel therapies for rare, immune-mediated inflammatory diseases (IMIDs) is limited due to small patient populations. Patients with Behçet's disease (BD), idiopathic inflammatory myopathy (IIM, also known as myositis) and IgG4-related disease (IgG4-RD) are treated with high-dosed glucocorticoids, methotrexate, azathioprine and mycophenolate mofetil, mostly for long periods of time with attendant risks of long-term toxicity, including infections. Therefore, there is an urgent need for new, more specific anti-inflammatory therapies such as targeted synthetic and biological disease-modifying antirheumatic drugs. Due to the role of type 1 interferon in both BD, IIM and IgG4-RD, JAK-STAT inhibition may be a promising treatment strategy in these conditions, because JAK1 is critical for the signal transduction of pro-inflammatory cytokine receptors. Previous research showed that JAK1 inhibition reduces activation of type 1 interferon-regulated proteins and key chemokines that control tissue inflammation.
A vizsgálat csoportja
- InterventionA vizsgált kezelés
26 weeks of Filgotinib once daily, 200mg, orally,
Kezelés: Filgotinib
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- Kérdések a feltételekről
- Forrás: NCT06285539: ki vehet részt
- Publikációk
- A regiszteradat frissítve
- 2026. május 12.